Highly Specialized Biologics Knowledge

Amgen brings extensive experience in innovator biologics to its biosimilars

Biosimilars development is a highly skilled, multistep process.¹ Amgen’s biologics expertise, gathered over four decades, means that we’re prepared for the task. We use the same processes, scientific standards, and quality systems for our biosimilars as we do for our innovator biologics.

“We use the same processes, scientific standards, and quality systems for our biosimilars as we do for our innovator biologics.”

Reference: 1. Camacho LH, Frost CP, Abella E, Morrow PK, Whittaker S. Biosimilars 101: considerations for U.S. oncologists in clinical practice. Cancer Med. 2014;3:889-899.

HK-09628-AMGEN-2022-Dec
Date of Approval: Dec 2022

previous: Therapeutic Area Heritage next: Discovery